An erectile dysfunction drug that reduces by half the time patients need to take the pill has been approved by the U.S. Food and Drug Administration.» Read More
The WHO’s recent warning about germs resistant to antibiotics has raised questions about what pharma companies are doing to fight this.
As rivals assessed what Pfizer's play for AstraZeneca could mean for the industry, one aspect touched nearly everyone: What it could mean for a U.S. tax loophole.
Ian Read, CEO of Pfizer, flew into London for a round of meetings with politicians and investors ahead of an expected fresh bid for AstraZeneca.
GlaxoSmithKline's sales fell 10%, highlighting the pressures behind last week's decision to trade more than $20 billion of assets with Novartis.
Merck reported better-than-expected quarterly earnings, helped by cost cuts and asset sales, but revenue came in slightly below expectations.
At the heart of Pfizer's pursuit of AstraZeneca is a shortage of products in its research pipeline, aggravated by a series of disappointing drug launches.
Pfizer's $100 billion offer to acquire British rival AstraZeneca is an effort to achieve an "efficient" tax structure, the company said.
Allergan may be more effective in its defense against a hostile takeover bid by Valeant Pharmaceuticals if it makes a purchase of its own, an analyst says.
U.S. drugmaker Eli Lilly reported lower-than-expected quarterly revenue as it was hurt by disappointing sales of its cancer and diabetes drugs.
The chief executive of AstraZeneca, at the center of speculation of a $101 billion takeover, has said such large-scale deals are "often disruptive."
Novartis posted first-quarter profit that beat expectations, boosted by an exceptional gain from the sale of its blood transfusion test unit.
Fracking presents no risk to Novozymes’ bioenergy business, the firm’s CFO told CNBC on Thursday, after it beat first-quarter profit expectations.
Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.
Gilead's net profit nearly tripled and revenue was more than $1 billion ahead of estimates, thanks to sales of a key Hepatitis C drug.
More than half the revenue from Botox comes from therapeutic, not cosmetic, use. And its potential is helping to make Allergan an attractive target.
One of Valeant's top shareholders on Tuesday threw his support behind its proposed takeover bid for Botox-maker Allergan.
The megabillion-dollar deals with Novartis also allow GlaxoSmithKline to "significantly expand" its world-leading vaccine business, GSK's CEO tells CNBC.
Pharmaceutical industry observers have been waiting for a rush of deals for months - and they might have finally arrived.
There are some solid reasons why Pfizer's reported $101 billion bid for AstraZeneca makes some sense, analysts said.
Activist investor William Ackman of Pershing Square Capital and Valeant Pharmaceuticals International are said to be pursuing a takeover of Allergan.
Get the best of CNBC in your inbox